五千人死了,药还没批Five Thousand Dead, No Drug Approved
5376人死亡,病死率超过50%,没有获批的治疗药物,也没有获批的疫苗。这不是一场天灾的统计数字,这是一次结构暴力的验尸报告。
加尔通的公式:Violence = Potential − Actual。埃博拉不是没有解。Ervebo疫苗对更常见的Zaire毒株有效,已经在用;针对Bundibugyo毒株的临床试验「最近几周」才刚刚开始。从5月中旬宣布疫情到11月临床试验启动,中间这几个月,五千多人死了。差额就是暴力。
为什么是Bundibugyo毒株?因为它罕见。罕见意味着没有商业价值,没有商业价值意味着没有药企愿意为它投入研发管线。药物和疫苗的生产逻辑不是「哪里死人最多」,是「哪里付得起钱」。刚果(金)、乌干达、肯尼亚的病人不在这个逻辑的分子里。
报道里有一个细节值得盯住:尼日利亚对两例疑似病例做了「两轮检测」,确认阴性。 Abuja在10月报告了十多年来首例输入病例,没有死亡。法国7月报告了一例从刚果(金)返回的医护人员感染。你看,病毒一碰到有检测能力、有追踪能力、有医疗资源的地方,就被拦住了。它杀死的是那些没有这些的地方的人。
这就是结构层和文化层联动的方式:结构上,疫苗研发和医疗资源按支付能力分配;文化上,非洲的疫情被叙述成「非洲的问题」,一个遥远的、可以折叠进一条简讯的数字。五千人死了,标题里连一个死者的名字都没有。
谁在共谋?不是某个恶人。是那套让「罕见毒株没有市场」显得理所当然的研发逻辑,是那套让非洲疾控中心的数据成为唯一信源、而全球公共卫生体系只负责「监测」的秩序。这套秩序里,刚果(金)的第17次疫情是一个统计事件,不是一场需要被终止的灾难。
临床试验开始了,这是好消息。但它来得太晚,而且它来的方式本身就在说明问题:不是先有药再等疫情,是疫情死了五千人,才终于凑够了启动试验的理由。
结尾的刺在这里:报道说尼日利亚的两例疑似「阴性」,法国的一例「没有死亡」。这些阴性结果被写进新闻,是因为它们让远离疫情的人安心。而刚果(金)那5372个死者,没有一个阴性结果可以让他们安心。
5,376 dead. A death rate above 50 percent. No approved treatment, no approved vaccine. This is not a natural disaster's statistics. This is an autopsy report on structural violence.
Galtung's formula: Violence = Potential − Actual. Ebola is not unsolvable. The Ervebo vaccine works against the more common Zaire strain and is already in use. Clinical trials for the Bundibugyo strain began only "in recent weeks." Between the outbreak declaration in mid-May and the start of those trials, more than five thousand people died. That gap is the violence.
Why Bundibugyo? Because it is rare. Rare means no commercial value. No commercial value means no pharmaceutical pipeline. Drugs and vaccines are not produced where the most people die; they are produced where someone can pay. The patients in the DRC, Uganda and Kenya are not in that numerator.
One detail in the report deserves attention: Nigeria ran "two rounds of testing" on two suspected cases and confirmed them negative. Abuja reported its first imported case in October, the first in over a decade, with no recorded deaths. France reported a single case in July, a health worker returning from the DRC. The virus meets testing capacity, contact tracing, medical resources — and stops. It kills where those things are absent.
This is how the structural and cultural layers work together: structurally, vaccine development and medical resources are allocated by ability to pay; culturally, an African outbreak is narrated as "Africa's problem," a distant number folded into a brief. Five thousand dead, and not one victim's name appears in the headline.
Who is complicit? Not some villain. It is the research logic that makes "no market for a rare strain" sound reasonable. It is an order in which Africa CDC data is the only source and the global public health system's job is "monitoring." In that order, the DRC's 17th outbreak is a statistical event, not a catastrophe to be stopped.
The trials have begun. That is good news. But they came too late, and the way they came proves the point: the drug did not wait for the outbreak; the outbreak had to kill five thousand before there was enough reason to start.
Here is the thorn: the report notes Nigeria's two suspected cases were "negative" and France's single case had "no recorded deaths." Those negative results are in the news because they reassure people far from the outbreak. The 5,372 dead in the DRC have no negative result to reassure them.